Skip to main content




Expert opinions on trends and controversies in autism research.

Previous articles

January 2013
Opinion / Viewpoint

Better biomarkers

by  /  4 January 2013

New funding will help Seaside Therapeutics, a Massachusetts-based company, develop biomarkers to track the success of treatments for autism, says Aileen Healy.

1 Comment
December 2012
Opinion / Viewpoint

How to undo stereotypes that hinder women in science

by  /  11 December 2012

Late this summer, a paper from Yale University researchers led by Jo Handelsman delivered some sobering news: There is still a clear bias against female scientists. The findings confirm the impression of many women in science, at all career levels, who feel undervalued.

Opinion / Viewpoint

Perspective: Imaging autism

by  /  6 December 2012

Several studies in the past two years have claimed that brain scans can diagnose autism, but this assertion is deeply flawed, says Nicholas Lange.

Opinion / Viewpoint

Perspective: Brain scans need a rethink

by ,  /  6 December 2012

Head movement can bias brain imaging results, undermining a leading theory on the cause of autism, say Ben Deen and Kevin Pelphrey.

November 2012
Opinion / Viewpoint

Defining language deficits across autism spectrum

by ,  /  27 November 2012

We are on the verge of a seismic shift in the definition of autism spectrum disorders, says David Skuse. Under proposed guidelines for autism diagnosis, the canard that most people with the disorder cannot speak, or have such disordered language that they cannot sustain a conversation, has been abandoned.

Opinion / Viewpoint

Oxytocin’s power

by  /  13 November 2012

A new study shows that long-term treatment with oxytocin, a hormone that typically enhances social bonds, can have unexpected consequences, says Sue Carter, a research scientist at RTI International.

Opinion / Viewpoint

Insights for autism from schizophrenia

by ,  /  13 November 2012

Lessons learned from postmortem studies of schizophrenia are applicable to research on autism, a disorder for which brain tissue has not been as well studied, say Allison Curley and David Lewis.

1 Comment
October 2012
Opinion / Viewpoint

Drug zone

by  /  26 October 2012

Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.

1 Comment
Opinion / Viewpoint

Transparent reports

by  /  19 October 2012

New standards for animal studies, including an emphasis on replicating results and the publication of negative findings, are vital for research progress, says Jacqueline Crawley.

Opinion / Viewpoint

Helpful hurdles

by ,  /  16 October 2012

Rapid progress in gene discovery and an emerging map of the molecular landscape of normal brain development are presenting unprecedented opportunities to unravel the biology of autism spectrum disorders, say Matthew State and Nenad Sestan.


Browse Articles by Topic

  • Genes
  • The Brain
    The Brain
  • Diagnosis
  • Signs and Symptoms
    Signs & Symptoms
  • Treatments
  • Environment
  • Science and Society
    Science & Society